{
    "2018-12-06": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Roche's Kadcyla Halves Death Risk in Breast Cancer Study",
                "features": {
                    "keywords": [
                        "Kadcyla",
                        "halves death risk",
                        "breast cancer",
                        "positive trial result"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study",
                "features": {
                    "keywords": [
                        "Emricasan",
                        "misses primary endpoint",
                        "mid-stage study",
                        "negative trial result"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}